Multimeric NKG2D for immunomodulation

Description:

NKG2D Biologic to Reduce Immune Cell Activation

 

A multimeric decoy to block activation of NKG2D and treat autoimmune and inflammatory diseases, and for use in vaccine development.

 

Dr. Roland Strong and Dr. Martin Prlic have developed a multimeric NKG2D decoy that will bind all NKG2D ligands and block the NKG2D pathway. NKG2D is a receptor expressed by immune cells which activates the immune cell upon ligand binding. While stimulation of NKG2D can be beneficial in some circumstances, its activation is associated with several autoimmune and inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and graft versus host disease (GVHD). NKG2D stimulation can also dampen the effectiveness of vaccine administrations. Blocking NKG2D stimulation can reduce immune cell activation as a treatment for autoimmune diseases, and for increasing vaccine efficacy.

 

<ul>

       <li>Therapeutic for autoimmune and inflammatory diseases</li>

       <li>Vaccine development</li>

</ul>

 

<ul>

       <li>Blocks NKG2D immune response</li>

       <li>Pan-NKG2D ligand masking through multiple ligand binding positions allows for lower dose with single therapeutic, in contrast with antibody-based therapeutics</li>

</ul>

 

Estimated that 50 million Americans have an autoimmune disease. In 2001, National Institutes of Allergy and Infectious Diseases (NIAID) estimated that annual autoimmune disease treatment costs were greater than $100 billion.

 

<ul>

       <li>Roland Strong, PhD, Vaccine and Infectious Diseases Division</li>

 <li>Veronika Groh-Spies, MD, Clinical Research Division</li>      

 <li>Thomas Spies, PhD, Clinical Research Division</li>

<li>Martin Prlic, PhD, Vaccine and Infectious Diseases Division</li>

</ul>

 

Preclinical <em>in vivo</em>, Preclinical <em>in vitro</em>

 

WO 2017083545

 

16-006StrongNKG2D.pdf

 

Natural Killer Group 2 member D | NKG2D| NKG2D ligands | reprogramming | lymphocyte receptor |plasticity | inhibitor | NKG2DL | enzyme activation | phosphorylation| biologic | vaccine | graft vs host disease | GvHD | inflammatory conditions | inflammatory diseases | autoimmune | neutralize |decoys | CD8 T cells | NK cells |  allergies | asthma | arthritis | gastrointestinal inflammation | neuroinflammatory | autoimmune | multimer

 

nkg2d-biologic-reduce-immune-cell-activation-16-006

Patent Information:
Category(s):
Therapeutic
Vaccine
For Information, Contact:
Ziyan Zhang
Technology Manager
Fred Hutchinson Cancer Research Center
zzhang3@fredhutch.org
Inventors:
Roland Strong
Martin Prlic
Mesfin Gewe
Thomas Spies
Veronika Groh-Spies
Peter Rupert
Keywords:
Protein / Peptide
© 2025. All Rights Reserved. Powered by Inteum